Mimicking Gene Defects to Treat Drug Dependence

@article{Sellers2000MimickingGD,
  title={Mimicking Gene Defects to Treat Drug Dependence},
  author={Edward Sellers and Rachel F. Tyndale},
  journal={Annals of the New York Academy of Sciences},
  year={2000},
  volume={909}
}
  • E. Sellers, R. Tyndale
  • Published 1 January 2000
  • Chemistry, Medicine
  • Annals of the New York Academy of Sciences
Abstract: The genetic basis for drug dependence has focused on genes that encode receptors involved in the reinforcing properties of drugs of abuse or that determine drug‐taking behavior (e.g. impulsivity, etc.). Pharmacogenetic variations in the patterns of metabolism among individuals can also importantly modulate the risk of drug dependence. Cytochrome P450 drug metabolizing enzymes (CYPs), can activate (e.g. codeine to morphine) or deactivate (e.g. nicotine to cotinine) drugs of abuse. Some… Expand
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.
TLDR
It is anticipated that pharmacogenetics will be used to identify individuals at a greater risk for specific drug dependencies, provide information that can lead to novel treatment and prevention approaches as well as provide guidance for individualization of treatment choice. Expand
Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes
TLDR
Evidence for the role of nicotine-metabolizing enzymes in smoking behavior and response to treatment is focused on and inhibition of the CYP2A6 enzyme to slow nicotine metabolism is a promising approach to increase nicotine availability and potentially reduce harm from tobacco smoking. Expand
Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.
Research into the relationship between genetics and drug response has focused on polymorphisms in genes that encode drug-metabolizing enzymes, particularly the genes of cytochrome P450 superfamily 2,Expand
Genetically determined metabolism of nicotine and its clinical significance.
TLDR
Type of the nicotine metabolism may be a potential predictor of the clinical outcomes in patients with cardiovascular disease, addicted to nicotine and in those using NRT. Expand
Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior
TLDR
It was shown that inhibiting CYP2A6 in vivo results in decreased smoking, making nicotine orally bioavailable, and the rerouting of procarcinogens to detoxifying pathways (20–22). Expand
MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
In vitro human studies show that the metabolism of most amphetamine-like psychostimulants is regulated by the polymorphic cytochrome P450 isozyme CYP2D6. Two compounds, methamphetamine andExpand
Clinical Pharmacogenomics of Drug Metabolizing Enzymes and its Clinical Application
TLDR
The genetic variation such as polymorphisms in drug metabolizing enzymes can affect the response of individuals to drugs that are used in the treatment of depression, psychosis, cancer, cardiovascular disorders, ulcer and gastrointestinal disorders, pain and epilepsy, among others. Expand
Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates
TLDR
Endogenous 5‐methoxyindolethylamines derived from 5‐hydroxytryptamine were identified as high‐affinity substrates of CYP2D6 that catalyzes their O‐demethylations with high enzymatic capacity and specificity, indicating a crucial step in a serotonin‐melatonin cycle. Expand
Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence
TLDR
Some of the recent findings on the influence of CYP2A6 genetic polymorphisms on nicotine kinetics, smoking behaviors, and how the gene appears to exert differential effects during various stages of smoking are reviewed. Expand
Genetic Influences on Smoking: A Brief Review
TLDR
The authors have reviewed some recent studies examining how genetic variations in drug-metabolizing enzymes and drug targets can influence the response to treatment with drugs such as bupropion and nicotine. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
TLDR
Cl cloning and sequencing of two types of mutant alleles of CYP2D6 isolated from genomic libraries of three PM individuals explain the absence of P450IID6 protein in livers of PM individuals and appears to be a common cause of polymorphic drug oxidation. Expand
Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
TLDR
This review discusses the molecular mechanism of two genetic polymorphisms, debrisoquine/sparteine (CYP2D6) coumarin (Cyp2A6) polymorphisms and elucidation of gene mutations of CYP2D 6 and CYP 2A6 in Japanese will be discussed. Expand
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
TLDR
It is demonstrated that the mutant 11.5-kb allele results from a deletion involving the entire functional CYP2D6 gene, which provides an explanation for the total absence of P450IID6 protein in the liver of these PMs. Expand
Cytochrome P450 2D6 and treatment of codeine dependence.
TLDR
Fluoxetine may have a role in the treatment of opiate dependence by decreasing opiate-reinforcing properties and inhibition of morphine formation in long-term users of oral opioid analgesics. Expand
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
TLDR
The data show the principle of inherited amplification of an active gene, and the finding of a specific haplotype with two or more active CYP2D6 genes allows genotyping for ultrarapid drug metabolizers. Expand
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
TLDR
Important interethnic differences exist in the structure of the CYP2D locus, and they suggest that the frequent distribution of the C188-->T mutation among the CYp2D6Ch genes explains the lower capacity among Chinese to metabolize drugs that are substrates of CYP 2D6, such as antidepressants and neuroleptic agents. Expand
The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.
TLDR
Data establish unequivocally that the debrisoquine polymorphism is the result of mutant CYP2D6 alleles and provide a framework to design a genetic test for this drug oxidation deficiency. Expand
CYP2A6 gene deletion reduces susceptibility to lung cancer.
TLDR
It is suggested that deficient CYP2A6 activity due to genetic polymorphism reduces lung cancer risk in a case-control study of Japanese subjects. Expand
Interethnic variation of drug metabolism.
  • W. Kalow
  • Biology, Medicine
  • Trends in pharmacological sciences
  • 1991
TLDR
Werner Kalow explains why the mere counting of a genetic variant may not be sufficient to uncover more major problems such as may be posed by multiple allelism or heterozygosity, and why it may be predicted that a large number of drugs will display interethnic differences in function. Expand
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
TLDR
A mutant allele of the CYP2D6 gene characterized by a 3-base-pair deletion in exon 5 (mutation D6-C) was previously presumed to be associated with the debrisoquine poor metabolizer phenotype and was analyzed by combining Xba I-restriction-fragment-length polymorphism analysis and specific CYP 2D6 mutation detection by polymerase chain reaction assays. Expand
...
1
2
3
4
5
...